https://www.selleckchem.com/pr....oducts/salubrinal.ht
SLE patients have elevated cardiovascular disease (CVD) risk, but it is unclear whether this risk is affected by choice of immunosuppressive drug. We compared CVD risks among SLE patients starting mycophenolate mofetil (MMF), cyclophosphamide (CYC), or azathioprine (AZA). Using Medicaid Analytic eXtract (2000-2012), adult SLE patients starting MMF, CYC, or AZA were identified and propensity scores (PS) were estimated for receipt of MMF vs CYC and MMF vs AZA. We examined rates of first CVD event (primary outcome), all-cause mortality,
Like
Comment
Share
